HCA Healthcare, Inc. (BVMF:H1CA34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 455.74B -2.9% |
| Revenue (ttm) | 404.17B +7.3% |
| Net Income | 35.44B +14.6% |
| EPS | 154.77 +25.9% |
| Shares Out | n/a |
| PE Ratio | 12.86 |
| Forward PE | 13.78 |
| Dividend | 0.54 (0.52%) |
| Ex-Dividend Date | Jun 15, 2026 |
| Volume | 2 |
| Open | 103.70 |
| Previous Close | 103.50 |
| Day's Range | 103.67 - 103.70 |
| 52-Week Range | 91.80 - 143.06 |
| Beta | 1.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 24, 2026 |
About HCA Healthcare
HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. The company owns, manages, and operates hospitals, ASCs, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, as well as rehabilitation and physical therapy centers, physician practices, home health agencies, hospices, outpatient physical therapy providers, home and community-based services providers, and various other facilities. Its general and a... [Read more]
Financial Performance
In 2025, HCA Healthcare's revenue was $75.60 billion, an increase of 7.08% compared to the previous year's $70.60 billion. Earnings were $6.78 billion, an increase of 17.78%.
Financial numbers in USD Financial StatementsNews
HCA Healthcare appoints Michael Schlosser as chief clinical officer
HCA Healthcare (HCA) announced that Michael Schlosser, M.D., MBA, senior vice president and chief transformation officer, has been appointed executive vice president and chief clinical officer, effect...
HCA Healthcare Announces Dr. Michael Schlosser as Executive Vice President and Chief Clinical Officer; Names Charles Gressle President of New Ambulatory Operations Group
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA) today announced that Michael Schlosser, M.D., MBA, senior vice president and chief transformation officer, has been appointed executi...
HCA Healthcare participates in a conferencce call with Truist
Truist holds a conference call with management on August 4 at 3 pm.
HCA Healthcare price target lowered to $475 from $525 at Mizuho
Mizuho lowered the firm’s price target on HCA Healthcare (HCA) to $475 from $525 and keeps an Outperform rating on the shares. The firm cites slower growth expectations post the…
HCA Healthcare price target lowered to $380 from $425 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on HCA Healthcare (HCA) to $380 from $425 and keeps an Underweight rating on the shares. While reduced 2026 guidance has reset expectations,…
HCA Healthcare price target lowered to $485 from $558 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on HCA Healthcare (HCA) to $485 from $558 and keeps a Buy rating on the shares.
HCA Healthcare price target lowered to $579 from $635 at UBS
UBS analyst AJ Rice lowered the firm’s price target on HCA Healthcare (HCA) to $579 from $635 and keeps a Buy rating on the shares.
HCA Healthcare price target lowered to $495 from $535 at Truist
Truist lowered the firm’s price target on HCA Healthcare (HCA) to $495 from $535 but keeps a Buy rating on the shares. The company’s Q2 admits were better though surgeries…
HCA Healthcare price target lowered to $476 from $540 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on HCA Healthcare (HCA) to $476 from $540 and keeps a Buy rating on the shares.
HCA Healthcare price target lowered to $380 from $425 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on HCA Healthcare (HCA) to $380 from $425 and keeps an Underweight rating on the shares. While lowered 2026 guidance “puts numbers in…
HCA Healthcare price target lowered to $485 from $520 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn lowered the firm’s price target on HCA Healthcare (HCA) to $485 from $520 and keeps an Outperform rating on the shares. The firm notes the company…
HCA Healthcare price target raised to $400 from $370 at BofA
BofA analyst Kevin Fischbeck raised the firm’s price target on HCA Healthcare (HCA) to $400 from $370 and keeps a Neutral rating on the shares. The firm cites a higher…
HCA Healthcare price target lowered to $393 from $396 at Baird
Baird lowered the firm’s price target on HCA Healthcare (HCA) to $393 from $396 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results…
HCA Healthcare price target lowered to $387 from $402 at Barclays
Barclays lowered the firm’s price target on HCA Healthcare (HCA) to $387 from $402 and keeps an Equal Weight rating on the shares. The firm updated the company’s model post…
HCA Healthcare price target lowered to $435 from $475 at KeyBanc
KeyBanc lowered the firm’s price target on HCA Healthcare (HCA) to $435 from $475 and keeps an Overweight rating on the shares. The firm notes Q2 matched preview, with a…
HCA Healthcare Earnings Call Transcript: Q2 2026
Q2 saw 11% EPS growth and strong insured volume, but a 15% drop in exchange patients led to a rise in uninsured volumes and a $400M EBITDA headwind, offset by Medicaid payments. 2026 guidance reflects these shifts, with revenue of $77–$79.5B and continued investment in capacity.
HCA Healthcare Earnings release: Q2 2026
HCA Healthcare released its Q2 2026 earnings on July 24, 2026, summarizing the period's financial results.
HCA Healthcare Quarterly report: Q2 2026
HCA Healthcare has published its Q2 2026 quarterly earnings report on July 24, 2026.
HCA Healthcare cuts FY26 EPS view to $28.70-$30.50 from $29.10-$31.50
Consensus $29.92. Narrows FY26 revenue view to $77B-$79.5B from $76.5B-$80B, consensus $78.49B. Cuts FY26 adjusted EBITDA view to $15.4B-$16.1B from $15.55B-$16.45B. Backs FY26 capital expenditures vi...
HCA Healthcare reports Q2 EPS $7.62, consensus $7.50
Reports Q2 revenue $20.23B, consensus $19.74B. Same facility admissions increased 2.5% and same facility equivalent admissions increased 2.7% in Q2. The company said, “During the second quarter, the C...
HCA Healthcare Reports Second Quarter 2026 Results
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2026. The Company's financial and operating re...
HCA Healthcare, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, July 22, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises HCA Healthcare, Inc., (“HCA" or the "Company") (NYSE: HCA) investors that the firm has initiated an investigation into possi...
HCA Healthcare price target lowered to $369 from $428 at Wells Fargo
Wells Fargo analyst Stephen Baxter lowered the firm’s price target on HCA Healthcare (HCA) to $369 from $428 and keeps an Equal Weight rating on the shares. The firm notes…
HCA Healthcare Stock Falls as Uninsured Patients and Declining Surgeries Dent Outlook
HCA Healthcare stock falls after the hospital chain operator lowers its full-year profit outlook as uninsured patients rise in the second quarter.
HCA Healthcare Shares Drop After Quarterly Earnings Squeezed by Payer Mix Shifts
The for-profit operator of healthcare facilities scaled back financial guidance for the year following payer mix shifts due to health insurance exchanges.